Funding for this research was provided by:
U.S. Department of Defense (W81XWH-19-1-0177 Log Number NF180027)
Received: 20 May 2022
Accepted: 15 August 2022
First Online: 26 August 2022
: ICES is a prescribed entity under Ontario’s Personal Health Information Protection Act (PHIPA). Section 45 of PHIPA authorizes ICES to collect personal health information, without consent, for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of, the allocation of resources to or planning for all or part of the health system. Projects that use data collected by ICES under section 45 of PHIPA, and use no other data, are exempt from REB review. The use of the data in this project is authorized under section 45 and approved by ICES’ Privacy and Legal Office.
: All authors agree with the final version and consent for publication.
: C. Barnett has received grant support from US Department of Defence, MGNet, Muscular Dystrophy Canada, Grifols and Octapharma. She has been a member of advisory board and consultant for Alexion, Sanofi and Argenx. E. Candido reports no competing interests. B. Chen reports no competing interests. P. Pequeno reports no competing interests. P. Parkin has received grant support from the Hospital for Sick Children Foundation and Canadian Institutes of Health Research. K. Tu reports no competing interests.